AOne-Year Open-Label Trial of Risperidone Augmentation in Lithium Nonresponder Youth with Preschool-Onset Bipolar Disorder

Pavuluri, Mani N.; Henry, David B.; Carbray, Julie A.; Sampson, Gwen A.; Naylor, Michael W.; Janicak, Philip G.

doi:10.1089/cap.2006.16.336

Cited by 89 publications

(42 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…51 Divalproex sodium plus risperidone or lithium plus risperidone in 37 patients promoted significant improvement in the YMRS, the CDRS-R, and the CGI-BP (p , 0.001). There were no significant between-group differences in terms of efficacy, safety, or tolerability.…”

Section: **mentioning

confidence: 97%

“…Data are summarized in Table 2. [40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59] Case reports and case series were detected, but were not included in the text due to the availability of higher-level evidence for the psychopharmacological agents of interest. Nevertheless, we recommend analysis of these case series and reports, which are available from the authors on request.…”

Section: Randomized Controlled Trials/meta-analysesmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacotherapy of bipolar disorder in children and adolescents: an update

Peruzzolo

Tramontina

Rohde

et al. 2013

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Objective: To review the options for acute and maintenance pharmacological treatment of bipolar disorder in children and adolescents, including the treatment of bipolar depression and comorbid attention deficit/hyperactivity disorder (ADHD). Methods: Narrative review of randomized clinical trials and open-label studies published from 2000 to 2012. The PubMed and PsycINFO websites were queried. Case series were included when a higher level of evidence was not available. Results: Published data from randomized controlled trials (RCTs) in acute mania/hypomania with significant responses are available for lithium, topiramate, risperidone, olanzapine, and aripiprazole. Open trials of lithium and lamotrigine show that these drugs may be effective in the treatment of depressive episodes. No trials of selective serotonin reuptake inhibitors (SSRIs) have been conducted. In the treatment of comorbid ADHD, there are encouraging findings with mixed amphetamine salts and atomoxetine; conflicting results are observed with methylphenidate. Conclusions: Published RCTs of traditional mood stabilizers are scarce, but the best available evidence (results from meta-analytic regression) suggests that second-generation antipsychotics (SGAs) as a group are more effective in reducing manic symptoms. Risperidone was the only one included in head-to-head comparisons (vs. lithium and divalproex), showing superiority in terms of efficacy, but with more metabolic side effects, which were also more common in most of the SGAs. There are few studies addressing the treatment of ADHD and depression. Brazilian guidelines for the treatment of pediatric bipolar disorder should also include some SGAs (especially risperidone and aripiprazole) as first-line treatment, and these drugs should be provided by the public health services.

show abstract

Section: **mentioning

confidence: 97%

Section: Randomized Controlled Trials/meta-analysesmentioning

confidence: 99%

Pharmacotherapy of bipolar disorder in children and adolescents: an update

Peruzzolo

Tramontina

Rohde

et al. 2013

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Open-label (OL) studies, with more homogeneously defined diagnostic criteria, have suggested that children treated with lithium achieve a response rate between 38% and 55% as monotherapy and 82% when used in combination with second-generation antipsychotics (SGAs) (e.g., risperidone) (11)(12)(13). In one OL lithium study of 100 adolescents (12-18 years of age) with an acute manic episode, 63% achieved response and 26% stayed in remission (14).…”

Section: Lithiummentioning

confidence: 99%

Management of Bipolar Disorder in Children and Adolescents

Patino¹,

Bruns²,

Witt³

et al. 2015

FOC

View full text Add to dashboard Cite

Treatment options for bipolar disorder have been primarily studied in adults. However, there is a growing body of research of these treatments in youths with bipolar disorder. Despite this there is still a huge gap in clinical trials performed on adults and children and as this manuscript will show, extrapolating results of adult studies doesn't necessarily translate to successful treatment in youths. Furthermore, although medication is the cornerstone of treatment in children and adolescents with bipolar disorder, psychosocial interventions are of paramount importance. The current manuscript will review the empirical evidence available for both pharmacological and psychosocial treatment strategies. In addition, evidence for the use of medications in different stages of bipolar disorder, including acute manic and mixed states and bipolar depression is addressed. The use of combination therapy, the treatment of pediatric bipolar disorder comorbid with other psychiatric conditions and the management of treatment resistant mania is also discussed.

show abstract

“…Metabolic side effects were a concern in the risperidone group. An open-label combination treatment study examined the efficacy of augmenting lithium treatment with risperidone in 38 children aged 4-17 with onset of bipolar disorder in preschool years [59]. There were 21 participants who were considered lithium non-responders after 8 weeks of monotherapy who received risperidone augmentation for up to 11 months.…”

Section: Atypical Antipsychoticsmentioning

confidence: 99%